Core Viewpoint - YKYY018 aerosol inhalation agent has received FDA approval for clinical trials aimed at preventing and treating respiratory syncytial virus (RSV) infections [1] Group 1 - The company, Yuyuan Pharmaceutical (688658.SH), announced that its wholly-owned subsidiary, Beijing Yuyuan Ketech Pharmaceutical Technology Co., Ltd., has obtained a Study May Proceed Letter from the FDA [1] - The IND number for the clinical trial is 178457 [1]

Core Viewpoint - YKYY018 aerosol inhalation agent developed by the company has received FDA approval for clinical trials aimed at preventing and treating respiratory syncytial virus (RSV) infections [1] Company Summary - The company’s wholly-owned subsidiary, Beijing YKANG Kechuang Pharmaceutical Technology Co., Ltd., has obtained the FDA's Study May Proceed Letter for YKYY018 [1] - YKYY018 is an internationally original membrane fusion inhibitor drug developed using the company's AI platform, specifically targeting RSV infections [1] - The product has a novel mechanism of action, binding specifically to the HR1 region of the F protein of RSV, inhibiting the formation of the 6-HB structure, and blocking the fusion process between the virus and host cells [1] - The company holds core patent rights for YKYY018 and possesses global exclusive rights to the product [1]

Core Viewpoint - The company has received approval from the U.S. Food and Drug Administration (FDA) to proceed with clinical trials for its inhalation aerosol YKYY018, aimed at preventing and treating respiratory syncytial virus (RSV) infections [1] Group 1 - The full subsidiary of the company, Beijing YKYY Technology Co., Ltd., is responsible for the development of YKYY018 [1] - The FDA issued a "Study May Proceed Letter" with IND number 178457, indicating regulatory approval for the clinical trial [1]

Core Viewpoint - The chemical pharmaceutical sector experienced a rise of 1.66% on November 26, with Frontier Biotech leading the gains, while the overall Shanghai Composite Index fell by 0.15% [1]. Group 1: Stock Performance - Frontier Biotech (688221) closed at 20.20, up 12.85% with a trading volume of 455,500 shares and a transaction value of 916 million yuan [1]. - Yuyuan Pharmaceutical (688658) closed at 26.88, up 12.00% with a trading volume of 218,600 shares and a transaction value of 577 million yuan [1]. - Fuyuan Pharmaceutical (6801089) closed at 24.53, up 10.00% with a trading volume of 113,800 shares and a transaction value of 274 million yuan [1]. - Other notable performers include Guangji Pharmaceutical (000952) with a 9.99% increase and Beida Pharmaceutical (000788) with a 9.94% increase [1]. Group 2: Fund Flow Analysis - The chemical pharmaceutical sector saw a net inflow of 43.08 million yuan from institutional investors, while retail investors contributed a net inflow of 23.8 million yuan [2]. - The sector experienced a net outflow of 281 million yuan from speculative funds [2]. - Key stocks with significant fund flows include Heng Rui Pharmaceutical (600276) with a net inflow of 231 million yuan from institutional investors [3]. Group 3: Individual Stock Fund Flow - New China Pharmaceutical (000756) had a net inflow of 68.2 million yuan from institutional investors, while experiencing a net outflow of 21.7 million yuan from speculative funds [3]. - Fuyuan Pharmaceutical (601089) saw a net inflow of 67.6 million yuan from institutional investors, with a net outflow of 39.4 million yuan from speculative funds [3]. - Other stocks like Beibete (688759) and Yuyuan Pharmaceutical (688658) also showed varying levels of net inflows and outflows from different investor categories [3].

（文章来源：证券时报网） | 证券代 | 证券简 | 今日涨跌幅 | 今日换手率 | 半年线 | 最新价 | 乖离率 | | --- | --- | --- | --- | --- | --- | --- | | 码 | 称 | （%） | （%） | （元） | （元） | （%） | | 601089 | 福元医 药 | 10.00 | 2.37 | 22.37 | 24.53 | 9.66 | | 600868 | 梅雁吉 祥 | 10.10 | 2.23 | 2.88 | 3.16 | 9.62 | | 688658 | 悦康药 业 | 12.00 | 4.86 | 24.55 | 26.88 | 9.49 | | 688209 | 英集芯 | 11.93 | 5.68 | 19.68 | 21.48 | 9.17 | | 002187 | 广百股 份 | 9.95 | 6.05 | 6.60 | 7.18 | 8.80 | | 920726 | 朱老六 | 13.18 | 21.64 | 20.63 | 22.41 | 8.62 | | 600227 | 赤天化 | 10.16 | 7.49 | 2 ...

证券时报·数据宝统计，截至今日上午收盘，上证综指3875.48点，收于半年线之上，涨跌幅0.14%，A股 总成交额为11439.39亿元。到目前为止，今日有140只A股价格突破了半年线，其中乖离率较大的个股有 悦康药业、福元医药、梅雁吉祥等，乖离率分别为9.77%、9.66%、9.62%；欣天科技、锡南科技、地铁 设计等个股乖离率较小，刚刚站上半年线。 11月26日突破半年线个股乖离率排名 | 证券代 | 证券简 | 今日涨跌幅 | 今日换手率 | 半年线 | 最新价 | 乖离率 | | --- | --- | --- | --- | --- | --- | --- | | 码 | 称 | （%） | （%） | （元） | （元） | （%） | | 688658 | 悦康药 | 12.29 | 4.11 | 24.55 | 26.95 | 9.77 | | | 业 | | | | | | | 601089 | 福元医 药 | 10.00 | 2.09 | 22.37 | 24.53 | 9.66 | | 600868 | 梅雁吉 祥 | 10.10 | 2.07 | 2.88 | 3.16 | 9.62 ...

Market Overview - The Shanghai Composite Index is at 3873.18 points, above the six-month moving average, with a slight increase of 0.08% [1] - The total trading volume of A-shares today is 805.55 billion yuan [1] Stocks Breaking Six-Month Moving Average - A total of 161 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Yuekang Pharmaceutical: 14.13% deviation, closing at 28.03 yuan, with a daily increase of 16.79% and a turnover rate of 3.63% [1] - Fuyuan Pharmaceutical: 9.66% deviation, closing at 24.53 yuan, with a daily increase of 10.00% and a turnover rate of 1.99% [1] - Meiyan Jixiang: 9.62% deviation, closing at 3.16 yuan, with a daily increase of 10.10% and a turnover rate of 1.96% [1] Additional Stocks with Positive Performance - Other stocks with notable performance include: - Guangbai Co., Ltd.: 8.80% deviation, closing at 7.18 yuan, with a daily increase of 9.95% and a turnover rate of 5.60% [1] - Chitianhua: 8.44% deviation, closing at 2.71 yuan, with a daily increase of 10.16% and a turnover rate of 4.61% [1] - Haiwang Life: 7.79% deviation, closing at 2.81 yuan, with a daily increase of 10.20% and a turnover rate of 2.89% [1] Summary of Other Stocks - Additional stocks with lower deviation rates that have just crossed the six-month line include: - Jiangsu Guoxin, Jinmei Technology, and Zhongyuan Haifa, which have just recently crossed the six-month moving average [1]

11月20日，悦康药业涨5.34%，截至发稿，报21.89元/股，成交1.18亿元，换手率1.21%，总市值98.50亿 元。 资料显示，悦康药业集团股份有限公司位于北京市北京经济技术开发区宏达中路6号，成立日期2001年8 月14日，上市日期2020年12月24日，公司主营业务涉及悦康药业定位于高端化学药的研发与生产,报告 期内主营业务收入主要集中在心脑血管药物、消化系统药物、糖尿病用药以及抗感染药物等。银杏叶提 取物注射液、天麻素注射液、注射用兰索拉唑、奥美拉唑肠溶胶囊、盐酸二甲双胍缓释片、注射用头孢 呋辛钠、注射用头孢曲松钠对公司收入贡献占比较大或未来增长潜力较大,是公司的主要产品。主营业 务收入构成为：心脑血管类55.67%，抗感染20.88%，原料药8.73%，消化系统类6.87%，降糖类4.85%， 其他2.62%，其他(补充)0.36%，技术服务0.02%。 从基金十大重仓股角度 责任编辑：小浪快报 华安中证1000指数增强A（015148）成立日期2022年7月12日，最新规模4593.8万。今年以来收益 24.74%，同类排名2011/4208；近一年收益23.09%，同类排名1859/39 ...

Investment Rating - The report does not explicitly provide an investment rating for the erectile dysfunction (ED) drug industry in China [1]. Core Insights - The Chinese ED drug market is experiencing strong demand and continuous growth, with a shift from traditional medical needs to broader sexual function enhancement [21]. - The market is characterized by increasing competition from domestic generic drugs and new drug developments, which are expected to intensify in the future [21]. - The leading products in the market, such as Sildenafil (Viagra) and Tadalafil (Cialis), have established strong brand recognition and market presence, making it challenging for new entrants to compete [16]. Summary by Sections Current Competitive Landscape - The competitive landscape of the Chinese ED drug market includes several key players with established products such as Sildenafil, Tadalafil, and others, with varying market entry dates and approval statuses [2]. - As of August 2025, the number of approved drug applications and suppliers for various ED drugs is as follows: Sildenafil (92 approvals, 53 suppliers), Tadalafil (172 approvals, 81 suppliers), and others [2]. Differentiation of New Drugs - New drugs like Sumenafil and Tonafadil are positioned with unique advantages, including lower effective doses, safety profiles, and potential for treating pulmonary arterial hypertension [7][9]. - Sumenafils' clinical trials indicate a lower incidence of adverse reactions compared to existing drugs, enhancing its market appeal [9]. Research Progress of PDE5 Inhibitors - The report highlights the ongoing research and development of PDE5 inhibitors, noting that the market is exploring new structural variants and indications beyond traditional uses [11]. - Traditional Chinese medicine is also recognized for its historical role in treating ED, with various herbal ingredients showing PDE5 inhibitory activity [11]. Market Demand and Future Trends - The demand for ED drugs is driven by both medical needs and psychological factors, with a growing acceptance of sexual health discussions in society [21]. - The market is expected to see an increase in competition from domestic companies entering through generics and innovative formulations, leading to a more dynamic market environment [21].

登录新浪财经APP 搜索【信披】查看更多考评等级 ● 本次会议是否有被否决议案：无 一、会议召开和出席情况 （一）股东大会召开的时间：2025年11月14日 （二）股东大会召开的地点：北京市北京经济技术开发区科创七街11号悦康创新药物国际化产业园一楼 会议室。 （三）出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及其持有表决权数量的情 况： ■ 证券代码：688658 证券简称：悦康药业 公告编号：2025-047 悦康药业集团股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： （四）表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东大会由公司董事会召集，董事长于伟仕先生主持，会议采用现场投票和网络投票相结合的表决 方式。本次股东大会的召集和召开程序、出席会议人员的资格和召集人资格、会议的表决程序和表决结 果均符合《中华人民共和国公司法》及《悦康药业集团股份有限公司章程》等规定。 （五）公司董事、监事和董事会秘书的出席情况 1、 ...